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SIGNIFICANCE 23
Capsule is a critical virulence factor in Klebsiella pneumoniae, in both antibiotic-resistant 24 classical strains and hypervirulent strains. Hypervirulent strains usually have a 25 hypermucoviscous (HMV) phenotype that contributes to their heightened virulence capacity, 26 but the production of HMV is not understood. The transcriptional regulator RmpA is required 27 for HMV and also activates capsule gene expression, leading to the assumption that HMV is 28 caused by hyperproduction of capsule. We have identified a new gene (rmpD) required for 29 HMV but does not contribute to capsule production. This distinction between HMV and capsule 30 production will promote a better understanding of the mechanisms of hypervirulence, which is 31 in great need given the alarming increase in clinical isolates with both drug resistance and 32 hypervirulence traits. 33
INTRODUCTION 35
Klebsiella pneumoniae has classically been considered an opportunistic pathogen associated 36 with infection of immunocompromised patients in nosocomial settings (1, 2) . Most infections 37 are caused by classical K. pneumoniae (cKp) strains and present as pneumonias or urinary tract 38 infections, sometimes leading to bacteremia and septic shock. The widespread occurrence of 39 extended-spectrum β-lactam resistant and carbapenem resistant strains has led both the CDC 40 and WHO to categorize K. pneumoniae at the highest level of concern for antibiotic resistant 41 threats (3, 4) . In addition, colistin and tigecycline resistant strains of K. pneumoniae have been 42 isolated, severely limiting treatment options (5). The deadly case of a pan-resistant cKp strain 43 (resistant to 26 antibiotics) underscores the immense challenge of treating Klebsiella infections 44 (6) . 45
In contrast to cKp, the hypervirulent K. pneumoniae (hvKp) are community-acquired by 46 immunocompetent individuals (7) . HvKp pathology is more severe than that typical of cKp and 47 can include pyogenic liver abscesses, necrotizing fasciitis, meningitis, and endophthalmitis (8, 48 9). Of particular concern is the emergence of strains with both hypervirulent (hv)-associated 49 genes or traits and the multi-drug resistance that is characteristic of cKp (10). Antibiotic 50 resistance genes are often encoded on plasmids (11, 12) and many of the genes corresponding 51 to hypervirulence are carried on large virulence plasmids or mobile genetic elements 52 incorporated on the chromosome (13-15). That these genetic entities can be horizontally 53 transferred suggests there is an increased risk of strains acquiring both hypervirulence and 54 multidrug resistance (16, 17) . Alarmingly, there have been recent reports of extensively 55 resistant hypervirulent K. pneumoniae (18, 19) , and multiple strains where both hv-associated 56 genes and antimicrobial resistance genes were present on the same mobile vector have been 57 documented (20-23). These reports of convergence of hypervirulence and antimicrobial 58 resistance in the same strain have heightened the need to better understand how 59 hypervirulence genes interface with a strain's genetic background to confer hypervirulent 60 phenotypes. This is particularly important given the extensive genetic diversity of genetic 61 content between K. pneumoniae strains. 62
Klebsiella virulence is largely attributable to LPS, pili, a polysaccharide capsule, and 63 siderophores, and these are present in virtually all pathogenic strains (2), heavy metal 64 resistance (24) and hypermucoviscosity (HMV) (2, 25, 26). Capsule is also linked to hypervirulence as the majority of hvKp have type K1 or K2 (27), although hv-associated traits 66 have been found in strains with other capsule types (28). Compared to cKp, hvKp produce a 67 thick 'hypercapsule' that is thought to contribute to the HMV phenotype. 68
RmpA is a LuxR-like transcriptional regulator frequently encoded on virulence plasmids or 69 on integrative chromosomal elements (ICEKp) and was initially discovered as a regulator of 70 HMV (14, 25). While the strong correlation between the presence of rmpA and hypervirulence 71 has made it a key biomarker for hvKp (27, 29), we still know very little about how rmpA 72 contributes to HMV and hypervirulence. Previous studies established that loss of rmpA 73 decreases capsule (cps) gene expression and reduces HMV in commonly used hvKp strains (30, 74 31). We recently confirmed these rmpA-dependent phenotypes in strain KPPR1S (26). We also 75 described another regulator of capsule gene expression, RmpC, which is encoded downstream 76 of rmpA; rmpA and rmpC are cotranscribed from the same promoter that is positively regulated 77 by RmpA (26). Like rmpA mutants, the rmpC mutant showed reduced cps gene expression but, 78 unlike rmpA mutants, retained HMV. We further showed that overexpression of rmpA in WT or 79 the ∆rmpA and ∆rmpC mutants increased HMV. However, overexpression of rmpA did not 80 restore cps expression in the ∆rmpC strain, and overexpression of rmpC elevated cps expression 81 even in the ∆rmpA strain (26). These data suggest that: 1) RmpA is an important determinant 82 for HMV but RmpC is not, 2) reduced cps expression in the ∆rmpA strain is likely a consequence 83 of reduced rmpC expression rather than direct regulation by RmpA, and 3) high levels of cps 84 expression are not necessary to confer HMV. This latter conclusion stems from the fact that the 85 ∆rmpC mutant has reduced cps expression but retains the HMV phenotype, and that exogenous 86 expression of rmpA in the ∆rmpC strain results in elevated HMV without restoring cps 87 expression. Importantly, this was the first clear evidence of a separation between capsule 88 expression and HMV and suggests that HMV is not simply a consequence of elevated capsule 89 production. 90
Furthering this work, we report here the discovery of a small protein, RmpD, encoded 91 between rmpA and rmpC that is essential for HMV. The ∆rmpD mutant is non-HMV, has no 92 change in cps expression, and produces the same amount of uronic acid (capsule) as the wild 93 type parental strain. This provides additional evidence that HMV and capsule result from 94 distinct processes. Expression of rmpD is sufficient to confer HMV to a ∆rmpA mutant. It is 95 transcribed by the promoter upstream of rmpA and therefore is also regulated by RmpA. Thus, 96 it appears that the loss of HMV and cps expression observed in rmpA mutants is due to reduced 97 transcription of rmpD and rmpC, respectively, and that the contribution of RmpA to these 98 phenotypes is as an activator of this operon. 99
100

RESULTS 101
RmpD is required for hypermucoviscosity. Having made the observation that 102 hypermucoviscosity (HMV) is not necessarily a consequence of elevated capsule expression 103 from examining the individual ∆rmpA and ∆rmpC strains with complementation plasmids (26), 104
we took one further step by similarly testing a strain that lacked the region encoding both rmpA 105 and rmpC (strain ∆rmpA-C). We predicted that introduction of pRmpA would restore HMV and 106 that pRmpC would restore manC expression. HMV was assessed by measuring the OD600 of 107 culture supernatants following low-speed centrifugation and expression of manC was 108 monitored using a promoter-GFP reporter (manC encodes an enzyme that makes one of the K2 109 sugar precursors and is located in the cps locus). While pRmpC resulted in elevated manC levels 110 as expected, pRmpA failed to restore HMV ( Fig. 1A, B ). However, introduction of a plasmid 111 containing the entire region that was deleted resulted in elevated HMV, and in normal levels of 112 manC expression (as previously observed), suggesting an element contained within the 113 intergenic space was necessary for HMV. In examining this region, we noted a predicted ORF in 114 the 375 bp region between the rmpA and rmpC genes (VK055_5098), but this predicted ORF is 115 encoded on the opposite strand (Fig. 1C ). The rmp locus encoded on the virulence plasmid of 116 NTUH-K2044 also indicates a predicted ORF downstream of rmpA (KP1_p021), but this one is 117 encoded on the same strand. The DNA sequence of these loci is very similar between KPPR1S 118 and NTUH-K2044, and the ORF prediction analysis in Geneious R11 identified an ORF in KPPR1S 119 nearly identical to KP1_p021. Thus, we cloned both predicted ORFs from KPPR1S into pMWO-120 078, transformed them into KPPR1S, ∆rmpA, ∆rmpC and ∆rmpAC strains, and assayed for HMV 121 ( Fig. 1D ). Introduction of pORF_5098 did not alter HMV, but the KPPR1S homolog of KP1_p021 122 (pRmpD) resulted in a hyper-HMV phenotype in all strains, including the ∆rmpAC strain. Thus, 123 this gene is required for HMV and was named rmpD. The region containing rmpD is within the 124 rmp operon ( Fig. S1 ). Although there is a predicted ORF of 58 amino acids in the DNA sequence 125 cloned in pRmpD, there remained the possibility that this region encoded a regulatory RNA. To 126 distinguish between these possibilities, we generated a plasmid with a rmpD-2xFLAG fusion and 127 were able to detect a FLAG-tagged protein of the predicted size ( Fig. 1E ), indicating that rmpD 128 encodes a protein and not a regulatory RNA. 129
To further analyze the role of RmpD, we constructed a strain lacking rmpD (∆rmpD) and 130 examined manC expression and HMV in this mutant. The ∆rmpD mutant had wild-type levels of Introduction of pRmpC into the ∆rmpD strain resulted in the same high levels of manC 134 expression observed in other strains but did not restore HMV. Complementation of ∆rmpD with 135 pRmpADC (formerly pRmpA-C) also resulted in an elevated level of HMV. The cultures in which 136 rmpD is overexpressed become extremely viscous and have the consistency of a thick syrup 137 ( Fig. S2 ), but have no change in transcription of manC ( Fig. S3 ). Collectively, these data suggest 138 that RmpD, rather than RmpA, is necessary for HMV. Given that RmpA regulates the promoter 139 driving expression of rmpADC (26), the well-established role of RmpA as a requisite factor for 140 the HMV phenotype is likely due to its function as a transcriptional activator of rmpD 141 expression. 142 143 Impact of rmpD in capsule mutants. Contributing to assumptions in the field that HMV is 144 derived from capsule, mutants in hvKp strains that produce no or reduced levels of capsule 145 have also typically been non-HMV (30-33). To further probe the distinction between capsule 146 and HMV, we transformed two capsule mutants (∆manC, ∆wcaJ) with pRmpD to determine if 147 these strains could become hyper-HMV. manC encodes a GDP-mannose pyrophosphorylase 148 that produces UDP-mannose, one of the sugar precursors of K2 capsule, and wcaJ encodes the 149 initiating glycosyltransferase (undecaprenyl phosphotransferase) involved in building the four-150 sugar K2 subunit. Both capsule mutants, with or without pRmpD, fully sedimented following 151 low speed centrifugation ( Fig. 3A ), suggesting that the HMV phenotype requires some capsule 152 biosynthetic enzymes and may require capsule production. We therefore examined capsule production in the ∆rmpD strain using the uronic acid (UA) assay. Curiously, there was no 154 decrease in UA levels in the ∆rmpD strain compared to WT, and addition of pRmpD did not lead 155 to increased UA (Fig. 3B ). Collectively, these data imply that production of capsule is not 156 impacted by RmpD, but that at least some components of capsule must be present in order to 157 become HMV. The negative stain, India ink, was used to visualize capsule. WT bacteria show 158 exclusion zones that vary somewhat in size, whereas the rmpD-deficient bacteria have thinner, 159 uniform clearing zones ( Fig. 4) . When rmpD is overexpressed in either strain, the bacteria have 160 uniformly large exclusion zones. As predicted, no exclusion zones were observed from staining 161 of ∆manC bacteria, although the field has ample bacteria present ( Fig. S4 ). Given that there is 162 no difference in the amount of UA between the WT and ∆rmpD strains, these data suggest that 163 the material forming the abundant exclusion zones is different than a typical UA-containing 164
capsule. 165
There are several known regulators of capsule gene expression, of which our lab has 166 identified three and studied five (26, 32). These mutants (∆rmpA, ∆rmpC, ∆kvrA, ∆kvrB, and 167 ∆rcsB) all have reduced UA levels and capsule expression, and all but ∆rmpC are non-HMV. To 168 further probe the factors necessary for HMV, we transformed the ∆kvrA, ∆kvrB, and ∆rcsB 169 strains with pRmpD and assessed HMV and capsule phenotypes. Each mutant had WT-like 170 HMV, elevated UA levels and elevated manC expression with the respective deleted gene 171 complemented in trans (Fig. S5 ). With pRmpD, the ∆kvrB and ∆rcsB strains became hyper-HMV 172 similarly to the WT strain, and an intermediate level of HMV was observed for the ∆kvrA strain 173 ( Fig. 3C ). Consistent with the results presented above, pRmpD did not restore UA production in these mutants ( Fig. 3D ), further implying that strains with low capsule expression and UA 175 production are still capable of becoming HMV. 176 177 rmpD contributes to immune evasion. One of the virulence phenotypes associated with 178 capsule is the blocking of adherence and phagocytosis (34). To determine if HMV specifically 179 contributed to these processes, we performed adherence assays with the macrophage-like 180 J774A.1 cells. Bacterial strains with pRmpD or vector were grown in the presence of inducer to 181 express rmpD, then allowed to interact with J774A.1 cells for 30 minutes. The cells had been 182 pre-treated with cytochalasin D to prevent phagocytosis, allowing measurement of attachment 183 only. After rinsing, the cells were lysed, and each sample was diluted and plated for bacterial 184 enumeration. The WT strain showed about 5% adherence (normalized to inoculum), and the 185 ∆manC mutant showed nearly 70% adherence (Fig. 5 ). The ∆rmpD strain behaved like the 186 acapsular manC mutant, with ~85% adherence. The WT or ∆rmpD strains with pRmpD were 187 virtually non-adherent, with less than 1% of the bacteria attached. This reduction was not 188 observed in the ∆manC mutant with pRmpD, most likely because it remains non-HMV. Because 189 the ∆rmpD strain still produces capsule at the level of WT, and the attachment phenotype is the 190 same as a capsule mutant, it appears that the HMV phenotype is the main factor blocking 191 attachment to host cells, and not capsule. Whether capsule has any protective role against 192 adherence, and likely phagocytosis, cannot be fully ascertained from these results, but it is clear 193 that HMV is important as the hyper-HMV strains were almost completely non-adherent. 194
Sequence and functional conservation of RmpD homologs. Examination of other hvKp strains 196
reveals that rmpD is present when rmpA and rmpC are present. There are three other hvKp 197 strains that are frequently used for the study of capsule expression and the RmpD proteins in 198 these strains share a high degree of identity ( Fig. 6A ). To test for functionality, the rmpD gene 199 from each of these strains was cloned and expressed in WT and ∆rmpD strains of KPPR1S. Not 200 surprisingly, each gene retained the ability to confer hyper-HMV in both WT and ∆rmpD strains 201 ( Fig. 6B ), suggesting that the role of RmpD in HMV is conserved among varying K. pneumoniae 202 isolates. 203
204
DISCUSSION 205
Hypermucoviscosity (HMV) is a phenotype possessed by a subset of K. pneumoniae strains and 206 is one of the phenotypes associated with hypervirulent strains (2). RmpA has been established 207 as an essential factor for HMV, and rmpA mutants also show reduced capsule gene expression 208 (26, 30, 31). Thus, it has long been assumed that the HMV phenotype was a consequence of 209 abundant capsule production in excess of that observed in classical strains. This arose despite 210 statements in early studies that HMV did not appear to be linked to capsule production (25, 211 35). However, FITC staining of an hv K. pneumoniae strain incubated with K2 antisera suggested 212 the extracapsular substance associated with HMV contained capsular material (36). Although it 213 has been 30 years since the discovery of RmpA, no direct regulation by RmpA of cps expression 214 (or other genes) has been demonstrated. In our investigations into the contributions of RmpA 215 to hypervirulence, we confirmed its role in HMV and cps expression, but also ascertained that 216 the mechanisms contributing to these phenotypes is much more complex than had been presumed (26). We identified a downstream gene encoding RmpC, a putative transcriptional 218 regulator that modulates cps expression, and found that rmpA and rmpC are in an operon that 219 is autoregulated by RmpA. RmpA and RmpC have overlapping and distinct functions, most 220 notably that the ∆rmpA mutant is non-HMV but the ∆rmpC mutant retains HMV. Both mutants 221 have a similar reduction in cps expression, however, overexpression of rmpC complements cps 222 expression even in strains lacking rmpA. While RmpC has also not been demonstrated to 223 directly regulate cps promoters, this data indicated that RmpA was not likely to be a direct 224 regulator of the cps genes. We thus concluded that RmpA controlled HMV while RmpC 225 controlled cps expression in work that provided the first clear evidence separating the 226 phenotypes of HMV and capsule levels. 227
In evaluating cps expression and HMV in what we thought was a double ∆rmpA-rmpC 228 mutant it became clear that the story was not as simple as suggested by the analysis of 229 individual rmpA and rmpC mutants. Namely, pRmpA did not restore HMV to this ∆rmpA-C 230 mutant but a plasmid containing the entire deleted region (pRmpADC) did restore HMV (pRmpC 231 does restore cps expression in this mutant). In this current study, we report the initial 232 characterization of RmpD, a small protein encoded in the region between rmpA and rmpC, also 233 within the rmp operon. The data presented here suggest that RmpD is the key factor driving 234 the HMV phenotype. Collectively, our data supports a model in which the role played by RmpA 235 in the HMV and cps expression phenotypes is to activate expression of rmpD and rmpC. This is 236 evidenced by 1) the restoration of HMV in the ∆rmpA and ∆rmpADC strains with pRmpD, and 237 restoration of cps expression in the ∆rmpA and ∆rmpADC strains with pRmpC, and 2) the 238 inability of pRmpA to restore HMV in the ∆rmpD strain or cps expression in the ∆rmpC strain.
Given that several RmpD orthologs were able to complement HMV in the ∆rmpD strain, and 240 that rmpD is present in strains that also have rmpA and rmpC, we speculate that RmpD is part 241 of a conserved mechanism conferring HMV to K. pneumoniae. 242
Several lines of evidence further support the notion that production of capsule and HMV 243 are separable. First, deletion of rmpD did not alter UA levels, suggesting that production of the 244 capsular material is unaffected by this mutation. Second, strains that are hyper-HMV from 245 overproduction of RmpD did not produce more UA than the WT strain. Third, trans expression 246 of rmpD in the regulatory mutants (∆rmpA, ∆kvrA, ∆kvrB, and ∆rcsB), that all have reduced cps 247 expression and capsule production, were all complemented for HMV. Each of these regulators 248 activate transcription of the rmpADC promoter; thus, the loss of HMV in these mutants is most 249 likely due to reduced expression of rmpD. Curiously, even though we can detect almost no 250 expression from the manC promoter in the ∆rcsB strain (26), introduction of pRmpD in the 251 ∆rcsB mutant, but not in the ∆manC mutant, results in hyper-HMV. Either very low levels of 252 mannose-1-phosphate guanylyltransferase are sufficient for HMV production, or HMV does not 253 actually require this enzyme and the HMV defect in a ∆manC strain is an indirect effect of loss 254 of this gene. 255
In mucosviscosity and adherence assays, the ∆rmpD strain behaves nearly identically to the 256 capsule mutant ∆manC. Both mutants pellet tightly and are highly adherent to host cells. The 257 hyper-HMV strains (WT and ∆rmpD with pRmpD) are essentially non-adherent, but the non-258 HMV ∆manC + pRmpD strain remains highly adherent. This raises the question as to whether or 259 not the anti-adherence property is dependent on capsule or on HMV. Given that the ∆rmpD 260 strain is encapsulated, it appears that HMV is a more critical determinant for blocking adherence, and quite likely, in blocking phagocytosis as well. This is consistent with the non-262 HMV ∆rmpA strain having a more severe virulence defect than the HMV-positive ∆rmpC strain 263 in the mouse pneumonia model (26). The limited data on the adherence and anti-phagocytic 264 properties of cKp strains makes it difficult to fully extrapolate the significance of capsule in 265 these processes. As HMV has been established as contributing to virulence, rmpD mutants are 266 likely to be attenuated in vivo. Support for this comes from re-examination of the virulence 267 defects of the ∆rmpA and ∆rmpC strains. While it is possible that RmpA regulates additional 268 virulence factors, the loss of rmpD expression in the ∆rmpA mutant likely contributes to the 269 stronger virulence defect in the ∆rmpA mutant than that observed from the ∆rmpC mutant. 270 Similarly, analysis of KPPR1 genes essential for infection in a mouse pneumonia model 271 identified mutations in VK055_5096 as deficient for virulence (37). This orf is located 272 immediately upstream of rmpA (VK055_5097) and the transposon insertion quite likely 273 impaired expression of the rmp locus. Furthermore, the virulence plasmid-encoded rmpD gene 274 (along with rmpA and rmpC) was found to be associated with liver abscess formation by NTUH-275 K2044 (38). 276
Complicating the notion that HMV is not simply a consequence of overabundant capsule 277 production is that hyper-HMV did not occur in capsule-deficient mutants carrying pRmpD. This 278 suggests that strains can be capsule-positive/HMV-positive or capsule-positive/HMV-negative, 279 but not capsule-negative/HMV-positive. One possible explanation for this is that the HMV 280 material is capsular, but that its export is altered in the presence of RmpD. This situation would 281 mean that even reduced levels of biosynthetic enzymes such as those found in the regulatory 282 mutants are sufficient to yield the extra polysaccharides. A second explanation is that HMV is a 283 polysaccharide distinct from capsule, but that some cps-encoded functions are required to 284 produce this material. A third possibility is that the HMV material is a modified form of capsule. 285
The presence of RmpD could influence synthesis or export of the altered polysaccharide. That 286 capsule-like material is part of HMV material is supported by the K2-positive staining of the 287 HMV substance from a WT strain but not from non-HMV mutants (36). 288
To date, HMV has primarily been associated with hv K1 and K2 strains, but more than 130 289 capsule types of K. pneumoniae have been identified (39). Of significant concern is the number 290 of recent reports of strains with both carbapenem resistance and hv-associated genes, 291
including rmpADC. These strains are genetically quite distinct (including capsule type) from the 292 hvKp that have been circulating, and it is not known to what degree acquisition of the rmpADC 293 locus will impact HMV and virulence of these strains. While we have shown that RmpD from 294 either a K2 or K1 strain can confer HMV in a K2 strain, it is not clear if there is capsule type 295 specificity for this RmpD function. We also do not know, beyond a few cps genes, what, if any, 296 other genes are necessary to confer HMV or if these genes are conserved in all K. pneumoniae 297 strains. A better understanding of what is required for HMV and how genetic background 298 influences the HMV associated hypervirulent phenotypes will be important for determining the 299 risks associated with CR-cKp strains that acquire rmpADC. 300
301
MATERIALS and METHODS 302
More detail can be found in the Supplementary Information  303 Bacterial strains, plasmids and growth conditions. The strains and plasmids used in this work 304 are listed in Table S1 . E. coli strains were grown in LB medium at 37°C. K. pneumoniae were grown at 37°C in M9 medium supplemented with 0.4% glucose and 0.2% casamino acids (M9-306 CAA). Unless otherwise noted, saturated overnight cultures were diluted to OD600 = 0.2 and 307 grown for 6 h. Antibiotics were used where appropriate: kanamycin (Kan), 50 µg/ml; rifampicin 308 (Rif), 30 µg/ml, spectinomycin (Sp), 50 µg/ml. For expression of genes cloned into pMWO-078, 309 100 ng/ml anhydrous tetracycline (aTc) was added to the media at the time of subculture. The 310 primers used for cloning are listed in Table S2 . In-frame gene deletions in K. pneumoniae were 311 constructed by allelic exchange using pKAS46-based plasmids as described (26). 312
Complementation plasmids were constructed using pMWO-078 (40). Plasmids containing 313 promoter-gfp fusions were cloned in pPROBE-tagless (41). The gfp reporter and 314 complementation plasmids were introduced into K. pneumoniae by electroporation as 315 described (26). 316
Transcriptional gfp reporter assays. Relative fluorescent units (RFU) and OD600 were measured 317 from bacterial cultures diluted 1:10 using a Synergy H1 plate reader (Bio-Tek, Winooski, WI) and 318 a Bio-Rad spectrophotometer (Bio-Rad, Hercules, CA), respectively. Data are presented as 319 RFU/OD600, normalized to the activity from the wild type strain in each assay. 320 Assessment of capsule production and HMV. Uronic acid was measured essentially as 321 described (42). Mucoviscosity of liquid cultures was determined by measuring the OD600 of the 322 culture supernatant following low-speed centrifugation as described (26). 323
Immunoblotting. Whole cell lysates from cultures grown in M9-CAA with aTc for 6 h were 324 separated on 15% SDS-PAGE gels, transferred to PVDF membranes and probed with a-FLAG 325 antibody (Sigma, M2 monoclonal antibody) and detected with chemiluminescence. 326 Adherence assays. Adherence assays were performed essentially as described (32) inoculated at an MOI of 50, incubated 1 h then rinsed to remove non-adherent bacteria as 477 described in Material and Methods. WT, ∆rmpD and ∆manC strains carrying either the vector 478 (pMWO-078) or pRmpD were tested. Two-tailed Student's t test was used to determine 479 significance. ns, not significant; ***, p = 0.0001; ****, p > 0.0001. 480 481 Figure 6 . Conservation of rmpD. (A) RmpD from known hvKp strains. c, chromosomal copy; p, 482 plasmid copy; orange and blue boxes, residues conserved in chromosomal and plasmid copies, 483 respectively; gray boxes, non-conserved residues; *, fully conserved residues; red residues, 484 positively charged side chains. Accession numbers for these sequences are in the Supplemental 485
Info. (B) Mucoviscosity assay to test if plasmid-and chromosomally-encoded rmpD genes can 486 complement the ∆rmpD mutant for mucoviscosity. 487 Figure 2 . Analysis of ∆rmpD strain indicates RmpD but not RmpA is required for HMV. manCgfp expression (A) and mucoviscosity (B) were measured in WT and ∆rmpD strains with the indicated plasmids as described in Materials and Methods. Data were obtained after 6 h induction of plasmid-borne rmp genes. One-way ANOVA with Dunnett's post-test was used to determine significance using WT with vector as the reference. ns, not significant; ****, p > 0.0001. Figure 5 . HMV is an anti-adherence factor. J774A.1 cells pretreated with cytochalasin D were inoculated at an MOI of 50, incubated 1 h then rinsed to remove non-adherent bacteria as described in Material and Methods. WT, ∆rmpD and ∆manC strains carrying either the vector (pMWO-078) or pRmpD were tested. Two-tailed Student's t test was used to determine significance. ns, not significant; ***, p = 0.0001; ****, p > 0.0001. RmpD from known hvKp strains. c, chromosomal copy; p, plasmid copy; orange and blue boxes, residues conserved in chromosomal and plasmid copies, respectively; gray boxes, non-conserved residues; *, fully conserved residues; red residues, positively charged side chains. Accession numbers for these sequences are in the Supplemental Info. (B) Mucoviscosity assay to test if plasmid-and chromosomally-derived rmpD genes can complement the ∆rmpD mutant for mucoviscosity.
